Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Alkem Laboratories Ltd.

Alkem Laboratories

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Mid-cap - With a market cap of ₹597.63 Cr.

EX-Date	Purpose
25 05 2021	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2021; and (ii) to consider and recommend Final Dividend, if any, for the financial year ended 31st March, 2021. Kindly take note of the same.
06 08 2021	Quarterly Results
12 11 2021	Quarterly Results
04 02 2022	Interim Dividend & Quarterly Results
13 05 2022	Audited Results & Final Dividend
05 08 2022	Quarterly Results
11 11 2022	Quarterly Results
10 02 2023	Quarterly Results & Interim Dividend
19 05 2023	Final Dividend & Audited Results
10 08 2023	Quarterly Results
07 11 2023	Quarterly Results
09 02 2024	Interim Dividend & Quarterly Results
13 11 2024	Quarterly Results
07 02 2025	Quarterly Results & Interim Dividend
29 05 2025	Final Dividend & Audited Results

News

01-JAN-2024

Alkem Laboratories completes sale of unit in US for consideration of $7.96 million

All rights, title and interest in the land, improvements and personal property with respect to the said Facility are sold to M/s New Mill Capital Holdings LLC

10:41 AM

02-DEC-2023

USFDA concludes inspection at Alkem Laboratories’ API manufacturing facility in Maharashtra

At the end of the inspection, the Company has received Form 483 with three observations

03:42 PM

04-FEB-2025

Alkem Laboratories launches Kojiglo serum in India

With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment

06:04 PM

07-FEB-2025

Alkem Laboratories reports 6% rise in Q3 consolidated net profit

Total consolidated income of the company increased by 1.46% at Rs 3467.27 crore for Q3FY25

03:29 PM

07-JAN-2025

Alkem Laboratories to sell Pithampur manufacturing facility to Rubicon Research

The sale is part of an ongoing initiative of networking strategy and optimisation of manufacturing facilities

02:26 PM

07-JUL-2023

Alkem Laboratories enters into ophthalmology segment

The nationwide launch of the company’s ophthalmology product range ensures that patients across India have access to quality eye-care formulations

11:18 AM

07-OCT-2022

Alkem launches FDC of Dapagliflozin, Sitagliptin and Metformin for adults with Type 2 diabetes in India

Alkem’s Dapanorm Trio will have a significant role in reducing HbA1c in uncontrolled type 2 diabetic patients

09:21 AM

08-APR-2023

USFDA conducts inspection at Alkem Laboratories’ API manufacturing facility in Gujarat

At the end of the inspection, no Form 483 was issued

12:31 PM

08-JUL-2022

Alkem Laboratories’ Indore plant gets one observations from USFDA

The USFDA had conducted a Good Manufacturing Practice and pre-approval inspection from July, 1 2022 to July 7, 2022

11:09 AM

10-AUG-2023

Alkem Laboratories reports over 2-fold jump in Q1 consolidated net profit

Total consolidated income of the company increased by 15.44% at Rs 3,033.56 crore for Q1FY24

03:51 PM

10-DEC-2024

Alkem Laboratories gets nod to transfer trade generics business to M/s. Alkem Wellness

The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same

02:27 PM

10-FEB-2023

Alkem Laboratories reports 14% fall in Q3 consolidated net profit

Total consolidated income of the company increased by 15.48% to Rs 3,086.24 crore for Q3FY23

03:51 PM

10-OCT-2024

Alkem Laboratories signs licensing agreement with Sonnet BioTherapeutics Holdings

The licensing agreement is to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India

03:50 PM

11-NOV-2022

USFDA issues Form 483 with 3 observations to Alkem Laboratories’ St Louis plant

At the end of the inspection, the company received Form 483 with three observations

10:57 AM

12-MAR-2025

Alkem Laboratories launches ’Empanorm’ medicine in India

This ’Empanorm’ is use for the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF)

12:42 PM

13-MAR-2025

USFDA concludes BIMO inspection at Alkem Laboratories’ Bioequivalence Center

At the end of the inspection, no Form 483 was issued

04:30 PM

14-NOV-2022

Alkem Laboratories reports 38% fall in Q2 consolidated net profit

Total consolidated income of the company increased by 10.14% to Rs 3,130.04 crore for Q2FY23

05:16 PM

16-SEP-2022

USFDA concludes pre-approval inspection at Alkem Laboratories’ USA facility

At the end of the inspection, the company has received Form 483 with two observations

02:22 PM

17-MAR-2025

Alkem Laboratories’ arm to acquire 100% stake in Bombay Ortho

The company’s arm has executed Share Purchase and Share Subscription Agreement

11:11 AM

17-SEP-2024

Alkem Laboratories incorporates wholly owned subsidiary

Alkem Wellness has been incorporated to carry on the business in all kinds of drugs, pharmaceuticals, drugs formulation, etc

11:59 AM

18-DEC-2024

Alkem Laboratories to make equity investment in Sunsure Solarpark

The said investment will be completed by the end of April, 2025

11:43 AM

19-MAY-2023

Alkem Laboratories reports 37% fall in Q4 consolidated net profit

Total consolidated income of the company increased by 18.64% at Rs 2,971.27 crore for Q4FY23

03:00 PM

20-JUN-2022

USFDA conducts inspection at Alkem Laboratories’ manufacturing facility in USA

At the end of the inspection, the company has received Form 483 with three observations

10:16 AM

24-FEB-2023

USFDA issues EIR to Alkem Laboratories’ Indore manufacturing facility

The inspection has now been closed by the USFDA

10:23 AM

28-FEB-2024

USFDA issues EIR for Alkem Laboratories’ API manufacturing facility at Mandva

The inspection has been classified as Voluntary Action Indicated and was closed accordingly

03:47 PM

28-MAR-2024

Alkem Laboratories incorporates wholly owned subsidiary

Alkem Medtech has been incorporated for exploring the medical device segment mainly in the cardiovascular and orthopedic fields

03:55 PM

28-MAR-2024

USFDA concludes inspection at Alkem Laboratories’ manufacturing facility at Baddi

At the end of the inspection, the company has received Form 483 with 10 observations

11:42 AM

31-JAN-2023

Alkem Laboratories launches antibiotic medication for multiple drug resistance infections

The company’s product Zidavi is a novel combination of ceftazidime & avibactam

10:41 AM